ライフサイエンスコーパス: vaccine

1 nts that may bring us closer to an effective vaccine.

2 ated safety in human trials of an rVSV/HIV-1 vaccine.

3 mmunization with PC nanogel-adjuvanted pH1N1 vaccine.

4 NV4 infections or to a live attenuated DENV4 vaccine.

5 id fever, as compared with the current Ty21a vaccine.

6 ) after the introduction of the two-dose MMR vaccine.

7 rovide the basis for a B cell-mediated HIV-1 vaccine.

8 can help guide the rational design of an HIV vaccine.

9 ment of a Plasmodium falciparum multiantigen vaccine.

10 s for the potential success of a therapeutic vaccine.

11 ntigen candidate for a pediatric RSV subunit vaccine.

12 ees receiving the moderately effective RV144 vaccine.

13 valuate the candidate live attenuated dengue vaccines.

14 an aid in the design of novel glycoconjugate vaccines.

15 Both viruses lack vaccines.

16 ssociated with structural protein-based ZIKV vaccines.

17 on of latent HIV-1 infection by T cell-based vaccines.

18 develop single-dose and long-lasting rabies vaccines.

19 ve viral vector and has been used to develop vaccines.

20 allergen Bet v 1 for suitability as allergy vaccines.

21 e first clinical trials for therapeutics and vaccines.

22 ew neglected disease drugs, diagnostics, and vaccines.

23 l approach for rational design of early-life vaccines.

24 he design and development of future malarial vaccines.

25 al administration of then-standard influenza vaccines.

26 ly for gonorrhoea but also for meningococcal vaccines.

27 rference in protection between the different vaccines.

28 ate antiviral drugs, and the efficacy of new vaccines.

29 the development of active and passive HIV-1 vaccines.

30 relevant to these diseases and proposed EBV vaccines.

31 nd PCV2 DNA may be present in human food and vaccines.

32 on to systemic immunity achieved by injected vaccines.

33 solated or synthetic lipopeptides are potent vaccine adjuvants, interacting with cell surface TLR2 he

34 flammatory cytokine induction may qualify as vaccine adjuvants.

35 al challenges plague clinical translation of vaccine-adjuvants: reducing acute toxicities that result

36 All the DC-targeting vaccine administrations with poly-ICLC increased the low

37 we associated administration of the cholera vaccine after CRC diagnosis with decreased risk of death

38 The development of vaccines against complex intracellular pathogens, such a

39 ne development but yet there are no licensed vaccines against malaria based on antigens identified fr

40 To expedite the evaluation of vaccines against paratyphoid fever, we aimed to develop

41 as a model in the development of blood stage vaccines against vivax malaria.

42 RSV vaccine and antibody strategies are likely to be cost-ef

43 r laboratory abnormalities between the PfSPZ Vaccine and placebo groups, and only grade 1 (mild) loca

44 me was the incidence of adverse events among vaccine and placebo recipients throughout the study.

45 mparing the genetic sequence of viruses from vaccine and placebo recipients to the sequence of the va

46 in the eye involving FcRn and may facilitate vaccine and therapeutic development for other ocular sur

47 ns are important for further informing Ebola vaccine and therapeutic development.

48 als, and are being engineered as vectors for vaccines and cancer therapy.

49 es in glycosylation between H3N2 egg-adapted vaccines and circulating strains likely contributed to r

50 ies of neoantigen-specific CTLs than soluble vaccines and even 31-fold greater than perhaps the stron

51 ortant implications for biotherapies such as vaccines and monoclonal antibodies.

52 Vaccines and prophylactic antibodies against respiratory

53 unity effects with meningococcal serogroup B vaccines and the need for a booster dose to sustain indi

54 is virus; with the intent to rapidly develop vaccines and therapeutics.

55 to support development of improved influenza vaccines and vaccination strategies.

56 tive treatments, a preventive or therapeutic vaccine, and specific and sensitive tests and to diagnos

57 crocephaly: congenital Zika virus infection, vaccines, and larvicides.

58 cells specific for different immunodominant vaccine antigens can fail to protect for opposite reason

59 further development of this multifunctional vaccine approach for the treatment of synucleinopathies,

60 Research on vaccine approaches that can provide long-term protection

61 rst line of protection at these entry ports, vaccines are being developed to induce pathogen-specific

62 Although some of these vaccines are in clinical trials, a lack of knowledge abo

63 Multi-antigen vaccines are under development, and there are presently

64 Vaccines are under development, but efficacies are varia

65 his might be a useful strategy for filovirus vaccines as well.

66 ebrile seizures occurred after dose 1 of MMR vaccine at a known low increased risk (RI, 2.71; 95% CI,

67 y randomized (1:1:1:1) to receive either GBS vaccine at dosages of 0.5, 2.5, or 5.0 mug of each of 3

68 Eligible patients received live zoster vaccine at investigators' discretion.

69 considered 6612 (16%) to be eligible for MMR vaccine at the time of pretravel consultation.

70 de two doses of HRV with the standard infant vaccines at 6 and 10 wk of age or to provide standard in

71 Glycoconjugate vaccines based on isolated capsular polysaccharide (CPS)

72 nic environment and are targets for drug and vaccine-based control measures.

73 ng immune responses with an H5N1 inactivated vaccine boost.

74 es of diphtheria-tetanus-acellular pertussis vaccine by the end of 15 months of age.

75 te to the design of population-targeted AIDS vaccines by effectively capturing the diversity of curre

76 protective immune responses than inactivated vaccines by eliciting local mucosal immunity and systemi

77 However, nnAbs, readily induced by vaccines, can trigger antibody-dependent cellular effect

78 d GII.4c norovirus virus-like particle (VLP) vaccine candidate adjuvanted with alum and monophosphory

79 asion ligand that is a potential blood-stage vaccine candidate antigen; however, a naturally occurrin

80 This Ebola vaccine candidate elicited anti-Ebola antibody responses

81 dentified an effective ST2 neoglycoconjugate vaccine candidate that was identified using a medicinal

82 C virus [HCV] genotype 1a) gpE1/gpE2 (E1E2) vaccine candidate was previously shown by our group to p

83 38G mutant has several features for an ideal vaccine candidate, including significantly reduced neuro

84 otective efficacy using a broadly protective vaccine candidate.

85 PfSPZ-CVac is a highly efficacious vaccine candidate; when we are able to optimize the immu

86 Vaccine candidates against ZIKV are coming online, but i

87 ion and suboptimal immunogenicity of malaria vaccine candidates have slowed the development of a Plas

88 ress three different AMA1-DiCo-based malaria vaccine candidates to develop a vaccine cocktail.

89 -free virus, they are not induced by current vaccine candidates.

90 he wild-type HA from viruses selected as the vaccine candidates.

91 correlates of protection for avian influenza vaccines cannot be determined from clinical studies.

92 nal depots to health facilities and 14 of 48 vaccine carriers (29%).

93 cilities to explore the number of injectable vaccines children received during their 2- and 4-month v

94 ased malaria vaccine candidates to develop a vaccine cocktail.

95 This vaccine, collectively termed GP+RAP/alpha-syn, is capabl

96 of vaccine-serotype E coli was noted in the vaccine compared with the placebo group (0.149 mean epis

97 Blockade Ab avidity to the GI.1 vaccine component peaked at day 35 (7 days after dose 2)

98 ti-receptor monoclonal antibodies to deliver vaccine components to skin DC subsets.

99 dy design, location, follow-up duration, and vaccine composition posing challenges for public health

100 These effects are seen for almost all vaccines contained in global immunization programs and i

101 As our search for an efficacious malaria vaccine continues, the development of a whole-organism v

102 erval between doses, and drug partner), this vaccine could be used for combination mass drug administ

103 es and how immunization with fHbp-containing vaccines could affect the commensal flora have yet to be

104 ge groups was dominant when choice increased vaccine coverage by >/=3.25%.

105 nce and Great Britain, countries with higher vaccine coverage rates.

106 ted with a 4.0% increase in 1-dose varicella vaccine coverage.

107 as excellent targets for designing anti-CVA6 vaccines.Coxsackievirus A6 (CVA6) causes hand, foot and

108 l vaccines for TB are developed, venue-based vaccine delivery that targets high-risk demographic grou

109 ires with potential applications in rational vaccine design and immunotherapeutics.

110 Structure-based vaccine design depends on extensive structural analyses

111 ghlighting a major challenge in tuberculosis vaccine design.

112 ns may be a potential mechanism of universal vaccine design.

113 ating Ag presentation, with implications for vaccine design.

114 Vaccine designers have sought to restrict the conformati

115 ted outcome might occur with some Zika virus vaccine designs.

116 enAfriVac, a meningococcal group A conjugate vaccine developed for the African meningitis belt, an en

117 should serve as a useful benchmark for HIV-1 vaccine developers.

118 e data has the potential to advance rational vaccine development but yet there are no licensed vaccin

119 However, vaccine development has been confounded because of HCV's

120 oof of principle that can inform prospective vaccine development not only for gonorrhoea but also for

121 Based on prior flavivirus vaccine development programs, knowledge of flavivirus pa

122 human immunodeficiency virus type 1 (HIV-1) vaccine development programs.

123 ects on chronic pathology, natural immunity, vaccine development strategies, immune disorders, and dr

124 dy-mediated mucosal immunity while informing vaccine development.

125 odies (bNAbs) against HCV is a major goal of vaccine development.

126 Thus, they are attractive immunogens for vaccine development.

127 intramuscular delivery of a two-fold higher vaccine dose.

128 with no increase in titer following a second vaccine dose.

129 The mean proportion of routine vaccine doses received by children younger than 24 month

130 of diphtheria- tetanus-pertussis-containing vaccine (DTP3) coverage in polio high-risk districts of

131 dose and 1683264 recipients of standard-dose vaccines during 2012-2013, and 1508176 high-dose and 187

132 younger adults, and the impact of frailty on vaccine effectiveness (VE) and outcomes is uncertain.

133 lating strains likely contributed to reduced vaccine effectiveness during the 2016-2017 influenza sea

134 ody responses, and consequently might affect vaccine effectiveness.

135 f 35 participants in the Vi-PS group to give vaccine efficacies of 54.6% (95% CI 26.8-71.8) for Vi-TT

136 However, vaccine efficacy and direct effectiveness estimates have

137 bisco((R))-100 and CoVaccineHT(TM), enhanced vaccine efficacy and sterile protection following malari

138 okine production that can be used to promote vaccine efficacy and the treatment of infections and mal

139 clades of HPAI A(H5) viruses in Vietnam, the vaccine efficacy of bivalent poultry vaccine formulation

140 No statistically significant vaccine efficacy was found against the non-laboratory-co

141 B/subtype E (B/E) proteins demonstrated 31% vaccine efficacy.

142 ver, there are limited data validating their vaccine efficacy.

143 The T-11 COBRA HA vaccine elicited antibodies with HAI and neutralization

144 The protective vaccine elicited unconventional CD8 T cell responses tha

145 Of these vaccine-elicited V3-specific MAbs, nearly 20% (6/33) dis

146 grams and influence immune response for some vaccines even at the age of 24 months.

147 poliovirus transmission and oral poliovirus vaccine evolution model.

148 ends, significant decreases occurred for all vaccines except polio, with the trend of monthly decreas

149 A prophylactic vaccine exists and currently available antivirals can su

150 ith an adjuvant and a recombinant adenovirus vaccine expressing r30.

151 igh-risk demographic groups may improve both vaccine feasibility and the impact on transmission.

152 ose administration of inactivated poliovirus vaccine (fIPV) could increase IPV affordability and stre

153 Nowadays, there is no available vaccine for human leishmaniasis.

154 Even so, effectiveness of influenza vaccine for older adults has been reported to be lower t

155 There is no treatment or vaccine for the disease and no cell culture system to pr

156 pproach can be used to generate an effective vaccine for this virus.

157 As novel vaccines for TB are developed, venue-based vaccine deliv

158 ew therapeutic targets and develop effective vaccines for WNV infections.

159 Ideally, an effective vaccine formulation would deliver multiple tumor antigen

160 am, the vaccine efficacy of bivalent poultry vaccine formulations should be tested in the future.

161 es, might enable development of age-specific vaccine formulations to overcome suboptimal immunization

162 ted in 4 of 19 cold boxes (21%) transporting vaccine from subnational depots to health facilities and

163 and infants immunized with the alum/MNrgp120 vaccine (gp120 median fluorescence intensities [FIs] in

164 group (50 in the placebo group and 61 in the vaccine group).

165 d in the placebo group and three died in the vaccine group.

166 siblings born after the women received Tdap vaccine (group B; 58 mother-infant pairs).

167 infants immunized with the MF59/SF-2 rgp120 vaccine had higher-magnitude antibody levels than adults

168 xpanded access, the first time that an Ebola vaccine has been used in an outbreak setting outside a c

169 he quadrivalent human papillomavirus (4vHPV) vaccine has led to reductions in the prevalence of human

170 ination suggests that the bivalent HPV-16/18 vaccine has protective efficacy in men.

171 Successful experimental vaccines have been derived from naturally occurring, cel

172 Live attenuated influenza virus (LAIV) vaccines have been shown to provide better cross-protect

173 Although these vaccines have generated high titers of neutralizing anti

174 ination would be beneficial, but to date, no vaccines have made it to clinical trials.

175 urrent therapeutic options, yet experimental vaccines have not been successful to date, due in part t

176 Mucosal or epicutaneous delivery of vaccines helps target the inductive sites for SIgA respo

177 he results support an urgent need to address vaccine hesitancy in policy dialogues at the state and n

178 dentifies immune and metabolic correlates of vaccine immunity.

179 known about the molecular mechanisms driving vaccine immunity.

180 se m826 properties offer a template for H7N9 vaccine immunogens, a promising candidate therapeutic, a

181 further developed as an intranasal pediatric vaccine.IMPORTANCE RSV and HPIV1 are major viral causes

182 g the introduction of inactivated poliovirus vaccine in 3 countries that would make future NVIs more

183 d the comparative effectiveness of high-dose vaccine in preventing postinfluenza deaths during 2012-2

184 vers whose children got 3 or more injectable vaccines in a single visit reported being only comfortab

185 eing only comfortable with 1 or 2 injectable vaccines in a single visit.

186 TIONALE: Administration of tuberculosis (TB) vaccines in participants with previous or current pulmon

187 ts with an MF59-adjuvanted recombinant gp120 vaccine induced higher-magnitude, potentially protective

188 one can identify functional specificities of vaccine-induced immune responses.

189 ficacy would benefit from learning about the vaccine-induced immunity and identifying correlates of m

190 n cases where rapamycin is used to stimulate vaccine-induced immunity.

191 This SAM vaccine-induced type I IFN response has the potential to

192 iple cell surface receptors, suggesting that vaccine induction of multiple NAbs with distinct neutral

193 can be prioritized for vaccination, and the vaccine interventions are cost saving for all age and ri

194 m) microprojections that delivers dry coated vaccine into the skin.

195 Encapsulation of allergens or DNA vaccines into nanostructures may provide advantages comp

196 ea requiring hospitalization after rotavirus vaccine introduction in Africa.

197 31 December 2015 and estimated the impact of vaccine introduction on all-cause diarrhea admissions.

198 n pneumonia hospitalizations associated with vaccine introduction varied across the socioeconomic spe

199 nsportation capacity after inactivated polio vaccine introduction, but temperature fluctuations durin

200 receive tOPV (n = 315) or inactivated polio vaccine (IPV) (n = 299) at 39 weeks.

201 Immunologically, PLGA-KAg vaccine irrespective of not significantly boosting the m

202 d mouth disease in children worldwide but no vaccine is available against CVA6 infections.

203 ildren, yet no highly effective treatment or vaccine is available.

204 But even while the vaccine is being manufactured the circulating strains ca

205 Influenza vaccine is known to have suboptimal immunogenicity in tr

206 in synucleinopathy models, and the combined vaccine is more effective than the humoral or cellular i

207 low fever-dengue live-attenuated tetravalent vaccine is now being marketed.

208 ntinues, the development of a whole-organism vaccine is now receiving much scrutiny.

209 The development of multivalent vaccines is an attractive methodology for the simultaneo

210 nd placebo recipients to the sequence of the vaccine itself, a technique called 'sieve analysis', one

211 Killed whole-cell oral cholera vaccines (kOCVs) are becoming a standard cholera control

212 y of an avian H5N2 live attenuated influenza vaccine (LAIV H5N2) in healthy Thai adults and its primi

213 sity suggest that an effective VAR2CSA-based vaccine may require multivalent activity.

214 VSVDeltaG pseudovirion vaccines may prove as efficacious and have better safety

215 the 4-component protein-based meningococcal vaccine (MenB-4C).

216 Newly proposed candidate Zika virus vaccines might or might not succeed in raising safe, eff

217 campaign with a monovalent type 2 oral polio vaccine (mOPV2).

218 The RV144 Thai trial HIV-1 vaccine of recombinant poxvirus (ALVAC) and recombinant

219 ensity of acquiring mutations in response to vaccine or treatment with one or a cocktail of monoclona

220 e pediatric respiratory illness for which no vaccines or suitable antiviral drugs are available.

221 velopment of delivery platforms of genes for vaccines or therapy, as well as more rapid development o

222 Viability of BCG vaccine packaged in the caves and the mechanical strengt

223 Pneumococcal conjugate vaccines (PCVs) are highly effective in preventing invas

224 ough highly effective pneumococcal conjugate vaccines (PCVs) are used in national immunization progra

225 possibility for its use as a live-attenuated vaccine platform for ZIKV and other clinically relevant

226 uations during vaccine transport could cause vaccine potency loss that could go undetected.

227 e potential to provide an adjuvant effect on vaccine potency, or, conversely, it might establish a te

228 associated with protection and a measure of vaccine potential.

229 diseases (IPDs) remain the leading cause of vaccine-preventable childhood death, even though highly

230 that a single dose of a live-attenuated Zika vaccine prevents infection, testis damage and transmissi

231 mponents of the S. pneumoniae glycoconjugate vaccine Prevnar13 that contains CPS antigens from 13 ser

232 Therefore, for vaccine purposes, we have designed and characterized a r

233 Transient rVSV viremia was noted in all the vaccine recipients after dose 1.

234 and antibody responses were detected in all vaccine recipients.

235 tified by age: less than 20 years (varicella vaccine recommended), 20 to 59 years (no vaccine recomme

236 lla vaccine recommended), 20 to 59 years (no vaccine recommended), and 60 years or older (HZ vaccine

237 cine recommended), and 60 years or older (HZ vaccine recommended).

238 populations at heightened risk of widespread vaccine refusal.

239 c and mucosal immune responses elicited by a vaccine regimen containing Env cross-linked to a CD4-mim

240 No severe vaccine-related adverse events were reported.

241 iciency has developed, researchers have used vaccine responses as a tool to characterize the phenotyp

242 acilitate design of peptidomimetics to focus vaccine responses on protective epitopes.

243 At day 2, vaccine RNA titres were higher for adolescents and child

244 Two rotavirus vaccines, Rotarix (RV1) and RotaTeq (RV5), were licensed

245 virus 16/18 AS04-adjuvanted (AS04-HPV-16/18) vaccine schedules at months 0 and 6 (2D_M0,6) and months

246 A partial vaccine series provided considerable protection, but not

247 10(3) or more colony-forming units per mL of vaccine-serotype E coli was noted in the vaccine compare

248 ife OM episodes historically associated with vaccine-serotype pneumococci may impact the susceptibili

249 For non-vaccine serotypes, rates of progression among Bedouin an

250 wborn dendritic cells (DCs), which integrate vaccine signals into adaptive immune responses, might en

251 also evidence of herd protection against the vaccine-specific and cross-protective types in unvaccina

252 surveillance of sexual behaviors, alongside vaccine status, to predict future disease burden.

253 rated that vaccination with the VC2-EHV-1-gD vaccine stimulated robust IgG1 and IgG2a antibodies afte

254 equipment, and recorded temperatures during vaccine storage and transportation.

255 ABV expressing the attachment protein of CDV vaccine strain Onderstepoort succumbed to infection with

256 e attenuated infectious bursal disease virus vaccine strain PBG98.

257 lier viruses and WHO-recommended prepandemic vaccine strains representing these clades.

258 able to detect RNA from five currently used vaccine strains, AIK-C, CAM-70, Edmonston-Zagreb, Morate

259 ovide mechanistic guides to aid in design of vaccine strategies against fast mutating pathogens.

260 tanding of neutralizing mechanisms, multiple vaccine strategies have advanced to the stage of clinica

261 e describe the development of an alternative vaccine strategy encompassing the expression of ZIKV non

262 is site has been neglected in previous HIV-1 vaccine studies.

263 cination, although other constraints such as vaccine supply and delivery need to be accounted for bef

264 ession of pertactin, a bacterial adhesin and vaccine target, are emerging.

265 ralizing epitopes and serves as an important vaccine target.

266 The E coli O-antigen is a promising vaccine target.

267 rther impetus for the development of malaria vaccines targeting GLURP.

268 CPSs are important vaccine targets because they are easily accessible and r

269 vaccines were generally more potent booster vaccines than r30 with an adjuvant and a recombinant ade

270 e development of an effective maternal HIV-1 vaccine that could synergize with antiretroviral therapy

271 We have produced synthetic vaccines that induce strong peptide-specific CD8(+) T ce

272 There is an urgent need for a vaccine to combat the hepatitis C virus (HCV) pandemic,

273 eed to develop an efficacious and affordable vaccine to control canine-transmitted rabies in developi

274 ckpiled A(H5N1) A/Anhui/1/2005 (clade 2.3.4) vaccine to elicit cross-reactive antibody responses to t

275 or antilatency strategies and/or therapeutic vaccines to boost functional antibodies and assist in el

276 lowing vaccination with trivalent oral polio vaccine (tOPV) at 6, 10, and 14 weeks, infants were rand

277 duction, but temperature fluctuations during vaccine transport could cause vaccine potency loss that

278 the phase III clinical trials only the RV144 vaccine trial elicited significant protection against HI

279 , have been protective efficacy in the RV144 vaccine trial have important societal implications.

280 n primate (NHP) studies as well as the RV144 vaccine trial indicate that non-neutralizing antibodies

281 , suggesting possible protection against HPV vaccine types after a single dose of 4vHPV.

282 r non-PCV7 serotypes in equivalent period of vaccine use.

283 no change in the scheduled age of varicella vaccine, use of MMRV vaccine was associated with a 4.0%

284 Experimental CMV-based vaccine vectors expressing a single MHC class I-restrict

285 New vaccine virus strains are selected, replacing older stra

286 al inoculation, both animal species shed the vaccine viruses for a limited time but without noticeabl

287 data support the further development of both vaccine viruses to optimally prepare for the further spr

288 However no vaccine was able so far to induce bnAbs demanding their

289 eduled age of varicella vaccine, use of MMRV vaccine was associated with a 4.0% increase in 1-dose va

290 g vaccination with the unlicensed rVSV-ZEBOV vaccine was introduced under expanded access, the first

291 c mice immunized with subunit H1N1 influenza vaccine, we demonstrate the advantage of skin vaccinatio

292 Despite the tetravalent composition of the vaccine, we observed a neutralization bias in the induce

293 lung function, or radiology attributable to vaccine were observed.

294 vaccinated with a cocktail of six different vaccines were completely protected from challenge with i

295 and guinea pigs, the rLmIII/a30 and rLmI/h30 vaccines were generally more potent booster vaccines tha

296 13 and 2013-2014, when influenza viruses and vaccines were similar.

297 with adjuvants as well as adjuvanted subunit vaccines were successful in the induction of NAbs and T

298 have significant implications for intranasal vaccines, which deliver antigen to mucosal-associated ly

299 pment of personalized, autologous anticancer vaccines with broad applicability.

300 d 10 wk of age or to provide standard infant vaccines without HRV.

301 To combat this virus, an effective vaccine would have distinct advantages over current ther